It now appears clear that CFTR modulators commenced in individuals aged >12 years, and therefore with ‘lipotic’ pancreases, cannot prevent progression to diabetes despite their transformative impact on CF-related pulmonary disease [48]. This evidence concerns the gene CFTR and diabetes mellitus.